QC Analyst
About the job
- A bachelor's degree in chemistry, biochemistry, microbiology, or a comparable life-science field.
- Fluency in English.
- Strong knowledge of good laboratory practices and current Good Manufacturing Practices.
- Strong analytical skills and attention to detail in documentation and laboratory processes.
- Openness to working with new technologies and a continuous improvement mindset.
- Clear, open, and effective communication with internal and external stakeholders.
- Availability to work weekend shifts.
- Perform and document analytical testing on finished products, materials, and stability samples in accordance with GxP standards.
- Manage, store, and track samples to ensure traceability and accuracy.
- Conduct, interpret, and report microbiological monitoring within cleanrooms at the Baarle-Nassau site.
- Report technical complaints, deviations, or special situations within 24 hours of receipt.
- Maintain an orderly, safe, and compliant QC laboratory environment.
- Apply and follow safety, radiation, and laboratory regulations to prevent risks.
- Contribute to continuous quality improvement through proactive identification and solution-oriented actions.
- Dutch language skills in addition to fluent English.
- Ability to act quickly and prioritize with a strong sense of urgency.
About the company
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Get referred to Novartis
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ianalumab won FDA Breakthrough Therapy designation on January 16, 2026.
- Remibrutinib posted positive Phase III data in April 2026 and September 2026.
- The October 2, 2026 Abogen deal adds optionality across autoimmune RNA programs.
What critics are saying
- Entresto generic erosion hits in November 2026 after a September 2026 patent-loss setback.
- Reuters reported two late-stage failures in September 2026 erased nearly $30 billion.
- Novartis faces India pricing pressure over ribociclib; Kerala High Court scrutiny continues.
What makes Novartis unique
- Novartis pairs blockbuster execution with 2026 launches like Rhapsido and Itvisma.
- Its 2026 autoimmune push spans remibrutinib, ianalumab, and Abogen's ABO2203.
- CAS collaboration in September 2026 strengthens Novartis's AI-ready reaction data advantage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
-4%1 year growth
-3%2 year growth
-3%INVESTOR ALERT: Pomerantz law Firm investigates claims on behalf of investors of Novartis AG - NVS. Oct 08, 2026, 10:00 ET NEW YORK, Oct. 8, 2026 /PRNewswire/ - Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Novartis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On September 8, 2026, Novartis issued a press release "announc[ing] that the global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia." On this news, Novartis's American Depositary Share ("ADS") price fell $22.29 per ADS, or 13.93%, to close at $137.70 per ADS on September 8, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. SOURCE Pomerantz LLP
The case for regeneration over slowing decline. Novartis' President of Biomedical Research, Fiona Marshall, on what it would take for big pharma to go all in on longevity. When the person who runs research for one of the world's largest drug companies turns up at a longevity meeting, people notice. Fiona Marshall oversees around 5,500 scientists across nine Novartis research sites, and she sits on the company's Executive Committee. As one pharma attendee put it to me, why is someone like Fiona Marshall at a conference like this, rather than at a 10,000-delegate cancer congress? Longevity Ltd. sat down at the ARDD 2026 conference to find out why and explore where Novartis sees the real opportunities in the biology of aging, and the hurdles that stand between the field and an approved 'antiaging' drug. Aging as the root cause. Marshall, a Cambridge-trained neuroscientist who co-founded structure-based drug design company Heptares before senior roles at Merck & Co, says her interest in aging goes back more than a decade - and it comes straight out of the day job. "As head of research, we need to start with the understanding of the disease, and then from there, what are the best treatments," she says. "More and more over time, I keep seeing how aging is in fact the major cause of disease at the end of the day. Probably the most important cause." Decades of focus on genetic risk, she explains, have delivered some very effective therapies - but have also shown that genetics is only one factor interacting with environment and lifestyle. "When you think about what these other factors are that genetics interacts with, aging is one of the main ones," she says. Large data sets now make that link to disease - and the way factors like exercise modify it - "very much more mainstream science." That thinking runs through Novartis' Diseases of Aging and Regenerative Medicine (DARe) research area, which targets three fundamental aging processes - mitochondrial dysfunction, declining DNA repair and extracellular matrix alterations - supported by a data-driven 'Regeneration Engine'. Marshall points to a long Novartis heritage in aging biology, from mTOR and rapamycin to cardiovascular prevention and, more recently, musculoskeletal work in sarcopenia and osteoarthritis. "That led to thinking about regenerative medicine," she says. "Instead of just trying to slow the decline, is there a way you can regenerate healthy tissue?" Inflammaging - and not everyone ages the same way. Asked which aging pathways excite her most, Marshall goes straight to inflammation. She cites Novartis' CANTOS study of the IL-1β antibody canakinumab, which was designed to lower cardiovascular risk but also produced signals that "lowering inflammation actually had a beneficial effect on cancer outcomes." Even after Novo's ZEUS trial of IL-6 inhibitor ziltivekimab missed its cardiovascular endpoint this summer, she says interest in IL-6 biology remains. The real question is patient selection - and here she outlines what may be one of the most important ideas in the field. "Probably some people do have more inflammation-driven aging. Other people may have more metabolic-driven aging," she says. "Some may be more prone to DNA mutations - maybe they have lower DNA repair enzyme activity." Proteomic signatures are beginning to reveal these different pathways. "The next stage, I think, is to look at what we call aging endotypes," she explains - stratifying people by their dominant driver and matching them with different therapeutic approaches. Healthspan first, not lifespan. Does that mean Novartis is preparing to take a pan-aging drug to regulators? Not yet. "We're still very much focused on our core diseases, which are nearly all diseases of aging - cardiovascular disease, neurodegenerative disease, and even cancer," Marshall says. And she is clear about the goal. "Our aim is not to increase lifespan. It actually is to increase healthspan. My concern about going for lifespan until we've addressed healthspan is you are actually going to just increase disease burden, not reduce it - particularly neurodegenerative disease." Nor is prevention necessarily the industry's first move. As cardiovascular care improves, prevention trials get longer, larger and harder. Developers therefore target the highest-risk groups - often people who have already had an event. Going earlier is the ideal, she says, "except then you need a much safer drug, because you're treating a healthy person for the rest of their life." GLP-1 drugs, she notes, benefited from a decade of use in diabetes before moving into broader populations. Why regeneration could be the cheaper bet. This is where regeneration becomes so attractive. Many current treatments for diseases of aging, such as Alzheimer's drugs, slow progression - measurable in a trial, but patients "don't feel any better." Counterintuitively, Marshall argues that a regenerative drug could be less expensive to develop, not more. "It's easier to measure an improvement than a reduction in a decline," she says. It is also a far easier case to make to payers and prescribers than saying a patient has "had a six-month less decline over three years." Novartis has historically pursued regeneration with small molecules from phenotypic screening, but the toolkit has widened: oligonucleotides, siRNA, mRNA, gene therapy and cell therapy can now all be brought to bear. Partial cellular reprogramming is "an area that we're very interested in" and "quite compelling" in preclinical models, but still early. Cell targeting is technically difficult, and whole-body approaches carry safety risk - so she expects the first clinical steps to come in focused, contained systems such as a single organ. As for how Novartis would access such technologies: build, partner or acquire - "we will go where the best opportunity is, and quite often, if it's a new technology, we do it with a partner." Mining exercise biology with BioAge. One such partnership is with BioAge Labs. Novartis is particularly interested in exercise as "profoundly beneficial as an antiaging mechanism," and the collaboration combines BioAge's longitudinal, multi-omic human data sets with Novartis' exercise expertise. The aim is to find targets that both decline with aging and are increased by exercise - the interface where an exercise mimetic could ultimately emerge. Regulators, endpoints and the consortium question. On the panel earlier that day, Marshall was the first to say Novartis would join a collaborative effort to move the field forward. Pressed on what would bring big pharma in, her answer was unequivocal: "If the FDA came up with a roadmap for how to develop an antiaging drug, we would be right in there. That would be one of the major barriers to entry." But the roadmap has to be achievable. She recalls a former FDA official once floating the idea of a 100,000-person trial with survival endpoints across multiple diseases - a study that, Marshall says, could take decades and cost billions, and would be impracticable to take forward. The obstacle, in other words, is the arithmetic of survival endpoints; at that scale and over that timespan, few sponsors could realistically see such a trial through. Instead, she sees a composite endpoint: biochemical biomarkers such as organ clocks as they become better validated, combined with AI-enabled imaging of muscle, bone, joints, the heart and the brain. "If you had a composite measure of those types of endpoints, those could be more tractable than survival." Agreeing those endpoints, she argues, needs a pan-system consortium rather than an industry club - academia, hospitals, regulators, small biotechs and large pharma, typically with government co-funding. She points to the EU's Innovative Health Initiative as a model, with companies contributing data and know-how rather than cash. IP is not the obstacle: "These are things we all need to agree with the FDA. It's really pre-competitive, and it's for the benefit of everyone." The catch is time - such efforts outlast a single government term and need long-term commitment, building on population resources such as the US All of Us program and the UK's Its Future Health. The next ten years. So where will the field be in a decade? Marshall expects a far deeper mechanistic understanding of how aging drives the major diseases - the causal biology that reveals druggable targets. "In less than ten years, hopefully, you would be seeing drugs that have actually come out of this causal biology, at the interface of aging and existing diseases," she says. Those drugs, she suggests, could act as a proxy for understanding aging's contribution to disease - "that ultimately could then lead to potentially antiaging drugs." Coming from the head of research at one of the world's biggest pharma companies, that is a measured but significant signal: the door is open - and a credible regulatory roadmap could be the key that unlocks it. Read more of its on-the-spot coverage of ARDD 2026 - CLICK HERE.
Novartis presents new multiple sclerosis data at a specialist congress. Novartis will present new data on its multiple sclerosis portfolio at the MSToronto2026 specialist conference. October 7, 2026 04:18 The focus will be on the results of the approval-relevant studies Remodel-1 and Remodel-2 for the active ingredient Remibrutinib, which will be presented on October 23, according to a statement from Novartis on Wednesday. Remibrutinib is an oral BTK inhibitor being investigated in relapsing multiple sclerosis. In the Remodel studies, Remibrutinib was compared with the already approved active ingredient Teriflunomide. New data on Kesimpta (Ofatumumab) in pediatric and adolescent multiple sclerosis will also be presented as a late-breaking abstract. These are results from the phase III Neos study, in which Ofatumumab and Siponimod were compared with Fingolimod. Kesimpta is already approved for adults with relapsing multiple sclerosis. In addition, the pharmaceutical giant is presenting data from the Sthenos study, in which Kesimpta was investigated in previously untreated patients with relapsing multiple sclerosis. Further presentations concern pregnancy and lactation data on Kesimpta from the Prim and Katharos studies. Overall, the Novartis program at the congress includes 46 abstracts.
SAP puts the autonomous enterprise to work: AI no longer just makes recommendations but takes action. By: Trademagazin Date: 2026. 10. 07. 09:27 Hallgasd a cikket: SAP is entering a new phase of business artificial intelligence: at the SAP Connect 2026 conference in Las Vegas, the company unveiled new AI solutions that go beyond merely analyzing information and making recommendations - they are capable of executing specific business processes under human supervision. These new Joule Assistants are being deployed across areas ranging from finance and procurement to HR, sales, and supply chain management, bringing the operational model SAP calls the "autonomous enterprise" closer to reality. "This is a major breakthrough in the world of business artificial intelligence," said Christian Klein, CEO of SAP SE. "The era of the autonomous enterprise has arrived. Built on the SAP Business AI Platform, Joule and the SAP Autonomous Suite help organizations like Novartis, Nestlé, and PwC connect intelligence across all their business functions and achieve reliable business outcomes." At the conference, these customers also shared their experiences regarding how the autonomous enterprise concept is already generating tangible business value within their operations. "We co-developed and recently launched the SAP Joule Sourcing Assistant pilot project," said Christoph Buerki, Head of Procurement at Novartis. "Our vision is for AI-based agents to handle manual, time-consuming tasks, allowing procurement professionals to focus on strategy, building supplier relationships, and creating value." Jill Notz, Leader of Accounting and Business Services at PwC, explained that the Billing Assistant will fundamentally transform the billing processes of the firm's professional services division: the solution identifies anomalies and corrects accounting errors before invoices are sent out. The essence of the autonomous enterprise concept is that artificial intelligence should not operate as a standalone tool but rather integrate directly into the company's day-to-day operations. SAP's solutions are built upon business data, processes, rules, and permissions, enabling AI not only to provide answers but also to execute tasks within workflows. The company employs an open approach: using the Agent2Agent protocol, Joule can collaborate with other AI systems and agents while maintaining corporate control and auditability. "The next major step for AI will be its transition from pilot projects to an integral part of daily corporate operations," said Péter Hidvégi, Managing Director of SAP Hungary. "However, this requires AI that is not only intelligent but also reliable, verifiable, and capable of operating within a business context." Joule Work connects business processes using natural language. SAP has begun rolling out Joule Work to customers; this new AI-powered user interface enables employees to communicate with SAP systems in their own language and execute tasks that span both SAP and external data sources. The solution is powered by the SAP Knowledge Graph, which maps the relationships between more than seven million data fields, thereby ensuring the business context and reliability of the responses. Within SAP's own operations, Joule Work is already live for approximately 110,000 employees; the company's experience shows an average productivity increase of 20 percent in finance, HR, and procurement processes. AI that executes business processes. SAP's new Joule Assistants are taking over tasks across various business areas - tasks that currently require significant manual effort. - In finance, AI assistants support functions such as automating revenue recognition, preparing disclosures, and ensuring international trade compliance. During early deployments of the International Trade Assistant, the workload associated with the commercial classification of products was reduced by up to 50 percent. - In the supply chain, planners can transform the management of disruptions - tasks that previously took hours - into a resolution process initiated by a single approval across planning, manufacturing, and logistics. - In HR, managers can more easily determine the most effective way to address labor shortages, while employees can make more personalized and informed decisions regarding their benefits. - In procurement, decision-makers can identify cost-saving opportunities based on industry benchmarks while more effectively managing the full lifecycle of the external workforce. - Customer relations and sales
SAP CEO Klein: This is a breakthrough moment for business AI. Published: 06 October 2026 15:14 Reporting from SAP Connect 2026 in Las Vegas this week, Flexify learn that the German softwarehaus has been working to put the autonomous enterprise (that increasingly real, but still somewhat emergent and embryonic notion of an organisation with deeply embedded business context-aware agentic services running through it) finally to work for real. It is doing so by driving Joule Work, Joule Assistants and SAP Business AI Platform forward to help enable business operations in all verticals to turn business AI into trusted outcomes, across every core business function and the workflows within. Big statements and big words there, so how does SAP think it can pull this off? Automation demonstrations. Among the core missions for SAP Connect this year is the company's willingness to provide what it promises are verifiable showcase demonstrations that illustrate how Joule Work and Joule Assistants generate value for customers across every line of business. Let's just stop and define those branded products. SAP Joule Work - is described as a foundational capability within SAP's AI suite that orchestrates complex business workflows, automates cross-functional tasks, and manages end-to-end operational processes autonomously across enterprise applications. SAP Joule Assistants - this technology can be explained as role-based digital co-pilots embedded directly into SAP systems that help users interact with their core functions through natural language as they surface what SAP likes to call "contextual insights", with the aim of accelerating routine daily tasks. Christian Klein, CEO of SAP calls it "a breakthrough moment for business AI" in real terms. "The Autonomous Enterprise has arrived," said Klein. "With Joule and SAP Autonomous Suite, built on SAP Business AI Platform, we're helping organisations like Novartis, Nestlé and PwC connect intelligence across every function to deliver trusted business outcomes." At SAP Connect, these customers shared how the Autonomous Enterprise is already driving measurable value across their businesses. Christoph Buerki, head of procurement, Novartis (a Swiss pharmaceutical company developing innovative medicines and therapies) attended SAP Connect 2026 to explain how his team co-developed and recently launched a pilot of SAP's Joule Sourcing Assistant. "Our vision is for AI agents to handle the manual heavy lifting, enabling sourcing professionals to focus on strategy, supplier engagement and value creation," said Buerki. Jill Notz, chief accounting officer & business services leader at PwC, shared how she and her team think the SAP Billing Assistant will transform billing operations across its professional services business, flagging anomalies and resolving posting errors before invoices go out. A new AI user interface. SAP further stated that its SAP Autonomous Enterprise Scales Up Joule Work is beginning its customer rollout as a new AI user interface that lets workers interact with SAP services in their own language and complete work across SAP and third-party data. Grounded in business context drawn from SAP Knowledge Graph (an enterprise data architecture component that models complex business entities, relationships, and context to fuel what the company calls "groundable AI" across SAP systems), which maps more than 7 million data fields. At SAP and inside SAP, Joule Work is already live with 110,000 employees, with the company seeing 20% productivity gains across finance, HR and procurement. A select group of customers also is using Joule Work in their business environments. Customers control the autonomy. When a query is not enough, Joule Assistants execute operational work directly within business workflows, using established data, authorisations and audit trails. Customers control the level of autonomy. Underlining an adherence to openness here, SAP confirms that its approach is also open: through the Agent2Agent protocol, and Joule can connect with third-party AI and agents, bringing governed business context into broader AI workflows. At SAP Connect, SAP showcased how these capabilities generate outcomes across SAP Autonomous Suite: * In finance, controllers can automate revenue recognition, disclosures and trade compliance, with early deployments of the International Trade Assistant reducing trade classification effort by up to 50%. * In supply chain, planners can turn multi-hour disruptions into one-click resolutions across planning, manufacturing and logistics. * In HR, leaders can determine the best way to close workforce gaps, while employees can make smarter benefits choices tailored to their needs. * In procurement, decision makers can identify savings opportunities against peer benchmarks and manage the full contingent workforce lifecycle. * In customer experience, organisations can turn customer engagement into sales opportunities with AI-powered campaigns, quoting and customer workflows. * Across industries, SAP is collaborating with customers to apply AI to specialised industry processes, helping organisations in manufacturing, retail, commodity trading and asset-intensive industries improve decision-making, automate routine actions and build more resilient operations. The company promises that SAP Business AI Platform gives organisations "one place to build, contextualise and govern AI" across SAP and third-party environments. Tuning into Joule Studio. With Joule Studio, business users and developers can build and extend skills and agents from no-code to pro-code workflows, choosing from more than 70 AI models. SAP Business Data Cloud and SAP Knowledge Graph ground those agents in trusted business data and context, helping organisations select the right model for each use case and better manage AI value and consumption. Users appear to be excited by what they are seeing in the Early Adopter Care programme, as they scale capabilities across the business. Users appear to also be building a route to what can be called a "shared intelligence foundation" that gives both its people and agents access to the same trusted data, context and knowledge. This notion of the shared intelligence platform is (arguably, very) important as Flexify move out of the prototyping phase with agentic services and really start to embed them in live operational workflows where humans (remember them?) will naturally feel more comfortable next to agents if there is open, transparent and democratically shared intelligence. "SAP-managed governance helps organisations scale AI with transparency, accountability and control. AI Agent Hub in SAP LeanIX solutions provides a central inventory of enterprise agents, while SAP's independently ISO/IEC 42001-certified governance architecture supports regulatory requirements, established authorisations and auditable AI operations," noted SAP in a press statement. To help organisations adopt AI at scale, SAP's Business Transformation Management portfolio, including SAP Signavio, SAP LeanIX and SAP WalkMe solutions, provides the toolchain to analyse processes, govern applications and agents, and drive adoption across the enterprise. Embedded payments to Cloud ERP. SAP also announced that it is entering the payments market with SAP Pay, powered by Tereina, an SAP company. Embedded directly in SAP Cloud ERP, SAP Pay executes and reconciles payments within the same workflow when an invoice is due, reducing manual file handling and external processing dependencies, while giving customers greater control. SAP is extending the Autonomous Enterprise beyond SAP's own application portfolio through new partnerships that bring specialised intelligence directly into SAP workflows. A new partnership between SAP and Moody's Corporation is designed to embed Moody's supplier risk monitoring data into SAP Ariba Supplier Lifecycle and Performance. This gives procurement teams continuously updated insights into supplier financial health, operational risk and regulatory status at the point of decision. Organisations will be able to move from periodic risk reviews toward continuous monitoring, enabling Joule Agents to flag supplier risk signals and surface alternatives before disruption affects the business. Appropriately, SAP concluded its announcements this year by saying, in full, that press release materials were "created with the assistance of artificial intelligence", but that they were then reviewed by the editorial team. What should developers think next? Software application developers coding with, at, on or perhaps even through SAP's platform might now think about moving their mindset onward from writing static transaction logic to building agentic, context-aware micro-services. The company is clearly (like all enterprise software vendors) now pushing SAP's "Autonomous Enterprise" message as hard as possible; this means code will no longer operate in isolated silos; it must be designed to expose deterministic tools and data models directly to autonomous agents like Joule Assistants and Joule Work. Developers might also think about architecting for context more directly i.e., grounding agents requires structuring data against the SAP Knowledge Graph. Code must also now "explicitly define relationships and authorisations across standard schema fields" as a responsibility.